Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | PPARA | Q07869 | 14/20 | 0.55 |
| ▸ | PPARG | P37231 | 10/20 | 0.55 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | FABP2 | P12104 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2106690 | 1.00 | ADORA3 (0.58) | ADORA3PPARAPPARGPPARDOPRK1 | |
| SCHEMBL11548490 | 0.86 | ADORA3 (0.61) | ADORA3PPARAPPARGOPRK1MEN1 | |
| SCHEMBL8935669 | 0.84 | ADORA3 (0.60) | ADORA3PPARAPPARGPPARDOPRK1 | |
| SCHEMBL5141872 | 0.84 | ADORA3 (0.60) | ADORA3PPARAPPARGOPRK1MEN1 | |
| SCHEMBL8935672 | 0.84 | ADORA3 (0.60) | ADORA3PPARAPPARGPPARDOPRK1 | |
| SCHEMBL5369095 | 0.84 | ADORA3 (0.60) | ADORA3PPARAPPARGOPRK1MEN1 | |
| SCHEMBL13846158 | 0.84 | ADORA3 (0.60) | ADORA3PPARAPPARGOPRK1 | |
| SCHEMBL5367947 | 0.84 | ADORA3 (0.60) | ADORA3PPARAPPARGOPRK1MEN1 | |
| SCHEMBL1960387 | 0.84 | PPARG (0.62) | ADORA3PPARAPPARGOPRK1MEN1 | |
| SCHEMBL27845063 | 0.83 | PPARA (0.46) | ADORA3PPARAPPARGPPARDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158667-B2 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2012-04-17 | — | — | US | disclosed |
| WO-2010065024-A1 | TOPICAL TREATMENT OF CATARACTS IN DOGS | KADOR PETER F (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090082415-A1 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082415-A1 | Topical treatment of cataracts in dogs | AKR1A1, AKR1B1, AKR1C1 | ADORA3 1735/4885PPARA 376/4885PPARG 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.